HER2-Positive Metastatic Breast Cancer Patients Receiving Pertuzumab in a Community Oncology Practice Setting: Treatment Patterns and Outcomes

BACKGROUND: Pertuzumab (Perjeta(®)), a HER2/neu receptor antagonist, was approved by the US Food and Drug Administration in June 2012 for use in the first-line setting for patients with HER2-positive metastatic breast cancer (mBC). OBJECTIVE: This retrospective study investigated the clinical and de...

Descripción completa

Detalles Bibliográficos
Autores principales: Robert, Nicholas J., Goertz, Hans-Peter, Chopra, Pooja, Jiao, Xiaolong, Yoo, Bongin, Patt, Debra, Antao, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332306/
https://www.ncbi.nlm.nih.gov/pubmed/28063028
http://dx.doi.org/10.1007/s40801-016-0102-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332306/
https://www.ncbi.nlm.nih.gov/pubmed/28063028
http://dx.doi.org/10.1007/s40801-016-0102-5

Ejemplares similares